ISSN: 2306-6091

International Journal of Pharmaceuticals and Health Care Research (IJPHR)

IJPHR |Vol. 14 | Issue 2 Apr - Jun -2026

www.ijphr.com

DOI : https://doi.org/10.61096/ijphr.v14.iss2.2026. 358-365

Anti-Aging Drugs: Current Research and Future Prospects

Kantipudi Mohana Sudhatri[1], Ch. Naga Satya Sri[1], Gandrikala Srilekha[1], Vemavarapu Satish Kumar[2]

[1]*Intern, Clinoxy Solutions Pvt., Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University. Hyderabad. Telangana. 500085*

2Founder, Clinoxy Solutions Pvt., Ltd., KPHB 9th Phase, Kukatpally, Back Side Nexus Mall (Forum Mall), Near JNTUH University. Hyderabad. Telangana. 500085

*Author for Correspondence: **Kantipudi Mohana Sudhatri**
Email: mohanasudhatri2244@gmail.com

Published on: 14.05.2026
Published by: Futuristic Publications

Abstract: Aging is a complex biological process associated with gradual decline in cellular functions and increased risk of age-related diseases Modern anti-aging research focuses on targeting the fundamental mechanisms of aging to improve healthspan rather than only treating individual disorders. Geroprotective agents such as metformin, rapamycin, senolytics, NAD^+ precursors, spermidine, resveratrol, and GLP-1 receptor agonists have gained attention due to their effects on metabolism, inflammation, autophagy, cellular senescence, and mitochondrial function. Advances in geroscience have identified important aging-related pathways including mTOR, AMPK, nutrient sensing, and oxidative stress regulation. Emerging approaches such as artificial intelligence, precision medicine, and biomarker-based therapies are accelerating the discovery of new anti-aging interventions. Although several compounds show promising results in experimental studies, further clinical research is required to confirm their safety and effectiveness. Anti-aging pharmacology represents a growing field with potential to promote healthy longevity and reduce age-related disease burden.

Key Words: Aging, Anti-aging drugs, Geroscience, Longevity, Senolytics, Metformin, Rapamycin, and Healthspan.

Introduction:

Aging is a complex biological process characterized by the gradual decline of cellular and physiological functions, leading to increased vulnerability to disease, disability, and mortality. As global life expectancy continues to rise, there is growing interest in strategies that not only prolong lifespan but also improve health span the period of life spent in good health. This has fueled extensive research into anti-aging interventions aimed at delaying, preventing or reversing age associated functional decline [1,5].

Anti-aging drugs are pharmacological agents that target the biological mechanisms involved in the aging process to delay cellular and physiological decline, improve healthspan, and reduce the risk of age-related diseases. These compounds act on pathways such as cellular senescence, inflammation, metabolism, mitochondrial function and tissue repair with the goal of promoting healthier aging rather than simply increasing lifespan [2].

Anti-aging drugs, also known as geroprotective agents, represent a promising area of biomedical research. These compounds target fundamental mechanisms of aging, including cellular senescence, genomic instability, mitochondrial dysfunction, chronic inflammation, and dysregulated nutrient-sensing pathways. Unlike conventional therapies that focus on treating individual age-related diseases, anti-aging drugs seek to address the underlying biological processes that contribute to multiple disorders simultaneously [5].

Recent advances in molecular biology, genetics, and biotechnology have identified several candidate compounds with potential anti-aging effects. Agents such as metformin, rapamycin, senolytics, nicotinamide adenine dinucleotide (NAD^+) precursors, and sirtuin activators have demonstrated encouraging results in preclinical studies and early clinical trials. These findings have strengthened the concept that aging may be a modifiable biological process rather than an inevitable consequence of time [3,4].

Despite significant progress, numerous challenges remain including concerns regarding long-term safety, efficacy, optimal dosing and regulatory approval. Nevertheless, ongoing research continues to expand our understanding of aging biology and offers exciting opportunities for the development of novel therapeutic approaches. The future of anti-aging medicine lies in integrating pharmacological interventions with personalized healthcare strategies to promote healthy longevity and improve quality of life in aging populations.

History and Background of Anti-Aging Drugs:

During the late nineteenth and early twentieth centuries, aging began to be viewed as a biological phenomenon rather than an unavoidable consequence of life. Scientists such as Elie Metchnikoff proposed that aging might be influenced by physiological processes and environmental factors, laying the foundation for scientific investigations into longevity. This period also witnessed early rejuvenation therapies, including hormone-based interventions and glandular transplantation experiments, which, despite limited success, stimulated interest in developing medical strategies to counter age-related decline [7].

The modern era of anti-aging research emerged with advances in molecular biology, genetics and gerontology during the latter half of the twentieth century. Researchers increasingly recognized that aging is regulated by specific cellular and molecular mechanisms including DNA damage accumulation, oxidative stress, mitochondrial dysfunction, telomere shortening and cellular senescence[1]. These discoveries shifted the focus from treating individual age-related diseases to targeting the biological processes responsible for aging itself.

Major Milestones in Anti-Aging Drug Research:

Year	Major Development
1903	Early scientific proposals suggested that biological factors contribute to aging, encouraging research into aging mechanisms.
1993	Studies identified longevity-related genes associated with caloric restriction in yeast, demonstrating that lifespan could be genetically regulated.
2009	Rapamycin was shown to significantly increase lifespan in mice, providing strong evidence that pharmacological interventions can influence aging.
2013	The Hallmarks of Aging framework established the principal biological mechanisms responsible for aging and became the foundation of modern geroscience.
2016	The geroscience approach gained widespread acceptance, emphasizing that targeting aging mechanisms may prevent multiple chronic diseases simultaneously.
2020–Present	Clinical research expanded to evaluate senolytic therapies, NAD^+ precursors, AI-assisted drug discovery and personalized anti-aging medicine.

A major milestone occurred with the development of the geroscience concept, which proposes that modifying the underlying mechanisms of aging can simultaneously delay multiple chronic diseases. This led to the identification of compounds known as geroprotectors-agents capable of slowing biological aging and promoting healthy longevity. Experimental studies demonstrated that several drugs, including rapamycin, metformin, resveratrol, and senolytic agents, could extend lifespan and improve health span in model organisms [5,8.]

In recent years, the publication of the Hallmarks of Aging framework has provided a comprehensive understanding of the biological processes driving aging. This framework has guided the development of next-generation anti-aging drugs that target nutrient-sensing pathways, cellular senescence, inflammation, mitochondrial dysfunction and epigenetic alterations. Consequently, anti-aging

pharmacology has evolved from speculative rejuvenation practices into a rapidly advancing scientific discipline focused on extending healthy human lifespan and reducing the burden of age-related diseases [1].

Methods For Anti-Aging:

Cellular and Molecular Approaches:

Recent advances in anti-aging research have emphasized the promise of cell-based interventions for promoting healthy aging. These strategies focus on restoring cellular health through several key mechanisms:

- Metabolic Optimization: Modifying cellular metabolic processes to enhance efficiency, maintain function and support longer cellular lifespan.
- Elimination of Senescent Cells: Targeting and removing dysfunctional aged cells that contribute to chronic inflammation and impaired tissue performance.
- Stem Cell-Based Regeneration: Harnessing the regenerative potential of stem cells to repair damaged tissues and stimulate renewal of aging organs 1,9.

2. Cosmeceuticals and Topical Treatments:

Cosmeceuticals combine cosmetic and therapeutic properties to address various signs of skin aging. These formulations contain bioactive ingredients that support skin health and rejuvenation. Notable components include:

- **Retinoids:** Widely recognized for their ability to enhance skin texture, stimulate cell turnover and minimize the appearance of fine lines and wrinkles.
- **Vitamin C:** A powerful antioxidant that helps protect the skin from environmental damage while supporting collagen formation and improving skin brightness.
- **Peptides:** Bioactive molecules that encourage collagen synthesis, contributing to increased skin elasticity and firmness.
- **Plant-Derived Extracts:** Natural compounds such as epigallocatechin gallate (EGCG) and bakuchiol have demonstrated potential in protecting against photoaging and improving overall skin appearance [10].

3. Lifestyle-Based Anti-Aging Strategies:

Lifestyle interventions continue to play a fundamental role in promoting healthy aging and reducing the risk of age-related conditions. Research highlights several effective approaches:

- **Regular Physical Exercise:** Consistent participation in moderate-intensity physical activity can enhance overall well-being, improve cardiovascular health, and lower the likelihood of developing chronic diseases.
- **Healthy Dietary Habits:** Nutritional patterns such as the Mediterranean diet are associated with improved longevity, better heart health, and a reduced risk of major cardiovascular events.
- **Mind–Body Practices:** Activities including yoga and tai chi help manage stress, improve mental well-being and reduce inflammation, all of which contribute to healthier aging and improved quality of life [11].

4. Novel Compounds and Therapeutic Developments

Ongoing research continues to investigate compounds that may delay age-related decline and extend healthspan:

- **NAD+ Precursors:** These molecules are being explored for their ability to support cellular energy metabolism, DNA repair and mitochondrial function.
- **Metformin and Rapamycin:** Both agents have demonstrated promising effects on aging-related biological pathways in preclinical studies, although further clinical research is required to establish their long-term efficacy and safety in humans [3,4,12].

Classification of Anti-Aging Drugs:

Anti-aging drugs are commonly classified according to the biological pathways they influence and the mechanisms through which they promote healthy aging.

1. Metabolic Regulators

These drugs improve metabolic balance, regulate glucose utilization, and influence nutrient-sensing pathways associated with aging.

Examples

- Metformin
- GLP-1 receptor agonists
- SGLT2 inhibitors

2. mTOR Inhibitors

These agents suppress mTOR signalling, thereby enhancing autophagy and reducing excessive protein synthesis and improving cellular maintenance.

Examples

- Rapamycin (Sirolimus)
- Everolimus

3. Senotherapeutic Agents

These compounds target senescent cells that accumulate with age. Some remove senescent cells whereas others reduce their harmful inflammatory activity.

Examples

- Dasatinib
- Quercetin
- Fisetin
- Navitoclax

4. NAD^+-Enhancing Compounds

These molecules increase intracellular NAD^+ concentrations, supporting mitochondrial energy production, DNA repair and normal cellular metabolism.

Examples

- Nicotinamide Mononucleotide (NMN)
- Nicotinamide Riboside (NR)

5. Sirtuin Activators

These compounds stimulate sirtuin proteins involved in stress resistance, metabolic regulation and cellular survival.

Examples

- Resveratrol
- SRT2104

6. Autophagy Promoters

These agents enhance the cellular recycling process known as autophagy, facilitating the removal of damaged proteins and organelles.

Examples

- Spermidine
- Rapamycin

7. Antioxidant Agents

These compounds help reduce oxidative stress by neutralizing reactive oxygen species thereby protecting cells from age-related damage [1,2].

Examples

- Coenzyme Q10
- Melatonin
- Vitamin C

Anti-Aging Drugs:

Metformin

Metformin is one of the most extensively studied drugs in aging research. Originally developed for the management of type 2 diabetes mellitus, it has attracted attention because of its ability to activate AMP-activated protein kinase (AMPK), suppress hepatic glucose production, reduce oxidative stress, and improve insulin sensitivity. These actions collectively influence metabolic pathways associated with aging. Epidemiological studies have suggested that individuals treated with metformin may experience lower rates of cardiovascular disease, certain cancers, and overall mortality compared with non-users. The ongoing Targeting Aging with Metformin (TAME) trial aims to determine whether metformin can delay multiple age-related diseases in older adults [3].

Rapamycin

Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR), a signalling pathway that regulates cell growth, protein synthesis, and autophagy. Inhibition of mTOR has consistently increased lifespan in multiple animal models. Rapamycin promotes cellular maintenance by enhancing autophagy, reducing protein aggregation, and improving stem cell function. Although its immunosuppressive properties limit widespread preventive use, lower or intermittent dosing strategies are currently being investigated to minimize adverse effects while preserving anti-aging benefits [4].

Senolytic Drugs

Cellular senescence contributes significantly to aging by promoting chronic inflammation and tissue dysfunction through the senescence-associated secretory phenotype (SASP). Senolytic drugs selectively eliminate senescent cells while preserving healthy cells. The combination of dasatinib and quercetin has shown encouraging results in reducing senescent cell burden and improving physical function in preclinical and early clinical studies. Other senolytic compounds, including fisetin and navitoclax are currently under investigation for their therapeutic potential [9].

Nicotinamide Adenine Dinucleotide (NAD+) Precursors

Levels of NAD+, an essential coenzyme involved in cellular energy metabolism and DNA repair, decline with advancing age. Supplementation with NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has been proposed to restore intracellular NAD+ concentrations. Animal studies have demonstrated improvements in mitochondrial function, muscle performance and metabolic regulation. Human trials have confirmed increased NAD+ levels following supplementation although evidence supporting long-term anti-aging benefits is still evolving [12].

Spermidine

Spermidine is a naturally occurring polyamine that induces autophagy and supports cellular homeostasis. Research suggests that spermidine supplementation improves cardiovascular health, preserves cognitive function, and enhances longevity in experimental models. Dietary intake of spermidine rich foods has also been associated with reduced mortality in observational studies, making it an attractive candidate for healthy aging interventions [13].

Dasatinib and Quercetin

Dasatinib and quercetin are classified as senolytic agents, a group of compounds that selectively remove senescent cells from the body. Senescent cells are damaged cells that have permanently stopped dividing but remain metabolically active. As these cells accumulate with age, they release pro-inflammatory molecules and tissue-degrading factors collectively known as the senescence associated secretory phenotype (SASP). This chronic inflammatory environment contributes to tissue dysfunction and the development of age-related diseases [9].

GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for the management of type 2 diabetes mellitus and obesity. These drugs mimic the action of the naturally occurring GLP-1 hormone, which regulates blood glucose levels by stimulating insulin secretion in response to food intake, suppressing glucagon release, slowing gastric emptying, and increasing the feeling of fullness. As a result, they improve glycemic control and promote significant weight reduction [14].

Drug	Mechanism of action	Uses
Metformin	Activates AMP-activated protein kinase (AMPK), suppresses hepatic glucose production, improves insulin sensitivity and reduces oxidative stress.	May delay age-related metabolic disorders, improve cardiovascular health, reduce chronic inflammation and potentially extend healthspan.
Rapamycin (Sirolimus)	Inhibits the mechanistic target of rapamycin (mTOR) pathway thereby promoting autophagy and reducing excessive cellular growth and protein synthesis.	Enhances cellular maintenance, delays age-related functional decline, improves immune regulation and extends lifespan in experimental models.
Resveratrol	Activates sirtuin (SIRT1) signalling, enhances mitochondrial function and strengthens cellular antioxidant defences.	Supports metabolic health, reduces oxidative stress and inflammation and may protect against cardiovascular and neurodegenerative diseases.
Nicotinamide Riboside (NR)	Serves as a precursor for NAD+, an essential molecule involved in energy production and DNA repair.	May support mitochondrial function and cellular energy metabolism during aging.
Nicotinamide Mononucleotide (NMN)	Increases intracellular NAD+ levels, supporting enzymes involved in DNA maintenance and cellular metabolism.	Under investigation for improving muscle function, metabolism and age-related physiological decline.

Trends and Innovations in the Development of Anti-Aging Drugs:

The field of anti-aging drug development has evolved rapidly from treating individual age-related diseases to targeting the fundamental biological mechanisms responsible for aging itself. This paradigm shift has been driven by advances in geroscience, which recognizes aging as the primary risk factor for numerous chronic disorders, including cardiovascular disease, neurodegeneration, cancer, and metabolic dysfunction. Consequently, current drug discovery efforts focus on extending healthspan rather than simply increasing lifespan [5].

One of the most significant trends in anti-aging therapeutics is the identification of conserved molecular pathways that regulate aging across multiple species. Signalling pathways such as mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), insulin-like growth factor-1 (IGF-1) and sirtuin signalling have become important pharmacological targets because they regulate nutrient sensing, cellular metabolism, stress resistance and longevity. Drugs targeting these pathways have demonstrated lifespan extension and improved physiological function in several experimental models [1,5].

The development of senotherapeutics has emerged as a significant advancement in aging research. Senolytic drugs are designed to selectively remove senescent cells that accumulate with age and promote chronic inflammation through the senescence-associated secretory phenotype (SASP). In contrast, senomorphic agents reduce the harmful secretory activity of senescent cells without causing cell death, thereby minimizing tissue damage while preserving cell viability. These promising therapeutic approaches

are currently being investigated in clinical trials for several age-related conditions, including osteoarthritis, pulmonary fibrosis, and diabetic complications.[9].

Targeting cellular metabolism through nicotinamide adenine dinucleotide (NAD^+) restoration has emerged as an innovative approach to healthy aging. Age-associated decline in NAD^+ impairs mitochondrial function, DNA repair and cellular energy production. Supplementation with NAD^+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have demonstrated improvements in mitochondrial metabolism and metabolic health in preclinical studies while early clinical trials have confirmed increased intracellular NAD^+ concentrations [12].

Autophagy-enhancing therapies have also gained considerable attention as potential anti-aging interventions. Pharmacological compounds including rapamycin, spermidine and caloric restriction mimetics stimulate autophagy, facilitating the removal of damaged proteins and dysfunctional organelles. Enhanced autophagy improves cellular homeostasis and protects against neurodegenerative diseases, cardiovascular dysfunction and metabolic disorders associated with aging [4,13].

Artificial intelligence (AI) has transformed anti-aging drug discovery by accelerating target identification, compound screening, and drug repurposing. Machine learning algorithms can analyze large scale genomic, transcriptomic, proteomic and metabolomic datasets to identify novel aging-associated molecular targets. AI driven platforms also enable prediction of drug efficacy, toxicity and optimal molecular structures, substantially reducing the time and cost required for drug development.

Precision medicine has become an emerging trend in gerotherapeutic development. Individual differences in genetics, epigenetics, microbiome composition and lifestyle significantly influence the biological aging process and therapeutic responses. Integration of multi omics technologies with personalized biomarkers enables the development of individualized anti-aging interventions tailored to each patient's biological age rather than chronological age [6].

Epigenetic reprogramming has emerged as a promising breakthrough in regenerative medicine. Partial cellular reprogramming is designed to reverse age-related epigenetic changes without completely resetting cellular identity, allowing tissues to regain youthful characteristics while reducing the risk of tumor development. Although this approach is still in the experimental stage, preclinical studies have shown encouraging results, including enhanced tissue regeneration and improved restoration of normal cellular function.

Combination therapies are increasingly being investigated to target multiple hallmarks of aging simultaneously. Since aging is a complex and multifactorial biological process, combining agents that modulate inflammation, mitochondrial dysfunction, nutrient sensing, cellular senescence and oxidative stress may produce greater therapeutic benefits than single drug approaches. Rational drug combinations are expected to enhance efficacy while reducing adverse effects through lower individual drug doses.

Another emerging innovation involves the identification of reliable biomarkers that accurately measure biological aging and therapeutic efficacy. Epigenetic clocks, circulating inflammatory markers, metabolomic signatures and proteomic profiles are increasingly being incorporated into clinical trials to evaluate the effectiveness of geroprotective interventions. These biomarkers facilitate earlier assessment of drug responses and accelerate the clinical translation of anti-aging therapeutics.

Despite remarkable progress and several challenges remain before anti-aging drugs can be routinely implemented in clinical practice. Long-term safety evaluation, standardized clinical endpoints, regulatory approval pathways and validation of aging biomarkers remain critical issues requiring further investigation. Continued collaboration among geroscientists, clinicians, pharmacologists, computational biologists and regulatory agencies will be essential for translating laboratory discoveries into effective interventions that promote healthy aging [1,5].

Conclusion:

Anti-aging drugs represent a promising area of biomedical research aimed at delaying age related decline and improving quality of life. Current evidence suggests that compounds targeting metabolic pathways, cellular senescence, inflammation and cellular repair mechanisms may contribute to healthier aging. Drugs such as metformin and rapamycin have shown significant effects in laboratory models while senolytics, NAD^+ boosters, and other emerging therapies continue to be investigated. Despite major advances, aging itself is not yet an approved therapeutic target, and many interventions require further validation through long term clinical studies. Future developments in biotechnology, artificial intelligence and personalized medicine may improve the effectiveness of geroprotective strategies. The integration of pharmacological approaches with healthy lifestyle practices may provide the best opportunity for extending healthspan and supporting successful aging.

References:

1. López-Otín C, et al. The Hallmarks of Aging. Cell. 2013.
2. Kennedy BK, et al. Geroscience: Linking Aging to Chronic Disease. Cell. 2014.
3. Barzilai N, et al. Metformin as a Tool to Target Aging. Cell Metabolism. 2016.
4. Harrison DE, et al. Rapamycin fed late in life extends lifespan in mice. Nature. 2009.
5. Fontana L, Partridge L. Promoting health and longevity through diet. Nature. 2015.
6. Zhavoronkov A. Artificial intelligence for aging research. Aging. 2019.
7. Metchnikoff E. The Prolongation of Life. 1908.
8. Gems D, Partridge L. Genetics of longevity. Nature Reviews Genetics. 2013.
9. Kirkland JL, Tchkonia T. Senolytic Drugs: From Discovery to Translation. Journal of Internal Medicine. 2020.
10. Zouboulis CC. Skin aging and anti-aging strategies. Dermato-Endocrinology. 2012.
11. D'Adamo CR, others. Healthy diet for healthy aging. *Nutrients*. 2021
12. Rajman L, Sinclair DA. NAD+ boosting molecules. Cell Metabolism. 2018.
13. Eisenberg T, et al. Spermidine and longevity. Nature Medicine. 2016.
14. Drucker DJ. GLP-1 receptor agonists and metabolic health. Cell Metabolism. 2018.